secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000971
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed
--------------------------------------------------------------------------------

- First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.
- First patient dosed in colorectal trial at Netherlands Cancer Institute supported by Roche for MSI Low metastatic CRC.
- Received Notice of Allowance from USPTO for patent combining LB-100 with immunotherapies; also exclusive license agreement with NIH.
- Completed registered direct offering raising $1.05M for working capital and general corporate purposes.
- Two publications in Cancer Discovery and EMBO support LB-100's mechanism to force cancer cells to become vulnerable to immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225000971/0001641172-25-000971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225000971/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer